Featured Articles
-
Resin Replacement Study: Reduce The Supply Risk Of Protein A Resin
9/19/2022
Review a “universal” affinity resin for the processing of antibody-based biopharmaceuticals, given the wide range of targets (such as mAb/Fc-fusion/Fab) and good processing condition performance.
-
JSR Life Sciences Expands Its European Gene-To-GMP Biologics Manufacturing Facilities For Selexis And KBI Biopharma In Geneva, Switzerland
11/4/2020
JSR Life Sciences, LLC today announced that it is increasing its European footprint with a newly expanded, state-of-the-art facility that will co-locate primary European operations for its affiliate companies KBI Biopharma and Selexis SA. The two companies combined will occupy 8,700 square meters in the Stellar 32 campus within Geneva’s ZIPLO (Industrial Zone Plan-les-Ouates).
-
JSR Life Sciences Company KBI Biopharma, Inc. Promotes Dirk Lange To CEO
3/2/2020
JSR Life Sciences, LLC announced today that Dirk Lange will take over as president and chief executive officer of KBI Biopharma, Inc., a leading contract development and manufacturing organization (CDMO) and JSR Life Sciences affiliate company.
-
PeptiDream And JSR Begin A Joint Development Program To Identify Peptides Applicable To Affinity Chromatography
9/20/2019
JSR Corporation and PeptiDream Inc. have agreed to begin a joint development program to identify peptides applicable to the affinity chromatography*1 process used in the purification of biopharmaceuticals such as antibody therapeutics.
-
JSR Life Sciences, LLC Expands Through East Coast Center Of Excellence
7/11/2019
JSR Life Sciences, LLC announced recently that it has expanded its footprint and technical capabilities through the opening of its Applications Center of Excellence in Durham, NC.
-
JSR Life Sciences to present data on Next Generation Protein A Chromatography Resin at BPI 2015
10/20/2015
JSR Life Sciences announced today that it will release Amsphere™ A3, a next generation Protein A chromatography resin for advanced protein separation in downstream processing of therapeutic antibodies manufacturing at the IBC Life Sciences' BioProcess International Conference & Exposition.
-
Optimization Of A Protein A Chromatography Process
Four Protein A resins from leading industry vendors, were screened for use in a capture step for a Herceptin biosimilar. Multiple parameters were assessed for their performance against the platform resin.
-
Protein A Resin: Minimize The Impact Of Elution Buffer Selection
Variations in elution behavior of the protein A capture step requires more process development work and could have an impact on the polishing step in the downstream process.
-
Enhancing Performance Of A Novel Chromatographic Technology
Utilize a modular, lattice supported resin bed to enhance the performance of a novel chromatographic technology.
-
Purification Of Antibody Fragments, Single Domain Antibodies
This application note contains key information and recommendations regarding the affinity purification of VHH sdAbs and antibody fragments that contain a VH domain, but not an Fc region.